X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

X4 Pharmaceuticals

04/08/2026 22:56

X4 Pharmaceuticals Inc XFOR.OQ XFOR.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2026
The Boston Massachusetts-based  company is expected to report a 22.7% increase in revenue to $2.42 million from $1.97 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for X4 Pharmaceuticals Inc is for a loss of 18 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $12.00, about 193.4% above its last closing price of $4.09
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.21
-0.20
-0.16
Beat
20
Dec. 31 2026
-0.28
-0.35
-0.22
Beat
36.7
Sep. 30 2025
-0.71
-0.92
-0.69
Beat
24.7​
Jun. 30 2025
-4.30
-4.34
-3.47
Beat
20
​​Mar. 31 2025
-5.38
-4.44
0.04
Beat
100.9
Dec. 31 2024
-5.40
-5.25
-6.00
Missed
-14.3​
Sep. 30 2024
-4.50
-5.19
-5.40
Missed
-4.1
Jun. 30 2024
3.80
0.17
-2.10
Missed
-1,325.9
This summary was machine generated August 4 at 21:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)